{"id":2979,"date":"2026-02-02T14:30:00","date_gmt":"2026-02-02T06:30:00","guid":{"rendered":"https:\/\/www.cytopeutics.com\/?p=2979"},"modified":"2026-02-02T21:04:17","modified_gmt":"2026-02-02T13:04:17","slug":"autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial","status":"publish","type":"post","link":"https:\/\/www.cytopeutics.com\/zh-hans\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0","title":{"rendered":"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial."},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Background<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

We have previously demonstrated that mesenchymal stromal cell (MSC) may improve cardiac function and reduce scar tissue in end-stage cardiomyopathy when administered concurrently with revascularization (either cardiac bypass operation or coronary angioplasty). In this study we compared the effects of MSC with concurrent revascularization (Group A), MSC only (Group B) and revascularization only (Group C).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Methods<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Twenty-seven patients were recruited. All patients had anterior myocardial infarction previously and baseline cardiac function (left ventricular ejection fraction, LVEF) less than 40%. \u00a0 Patients who were suitable for revascularization were divided into Group A or C. Patients who have had revascularization previously or were unsuitable for revascularization were allocated to receive MSC by intracoronary infusion (Group B). Patients received between 50-100×10\u00b0 autologous bone-marrow MSC. The LVEF, LV end diastolic diameter (LVEDD) and interventricular septum thickness (IVST) were estimated at baseline, 3 months, 6 months and 12 months follow-up. Magnitude of change in LVEF (AEF) was calculated as percentage of baseline value.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Results<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

All patients patients tolerated tolerate the procedure well with no proarrythmia, calcification or tumor formation. There was no difference in baseline parameters between Groups A, B and C including LVEF (27.5+5.6 vs. 32.0+4.5 vs. 28.0\u00b18.3%; p=0.26). LVEF improved in groups A and B during follow-up. The improvements were statistically significant compared to baseline for Group B at 3 months and for Groups A and C at 6 months. The AEF was largest in Group A compared to Groups B and B and C at 12 months (130\u00b183 vs. 46+37 vs. 31\u00b129%; ANOVA p=0.02).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Conclusion<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MSC significantly improves cardiac function. Concurrent MSC administration with revascularization appeared to be superior to either procedure alone for patients with ischemic cardiomyopathy.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Affiliations<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
  1. Penang Adventist Hospital, Penang, Malaysia<\/span><\/li>
  2. Cardiology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia<\/span><\/li>
  3. Cytopeutics, Selangor, Malaysia<\/span><\/li>
  4. Radiology Unit, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia<\/span><\/li>
  5. Department of Medicine, The University of Hong Kong, Hong Kong<\/span><\/li>
  6. Tunku Abdul Rahman University, Selangor, Malaysia<\/span><\/li>
  7. Cell Therapy Center, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia<\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
    \n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t
    \n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tDownload paper<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Background We have previously demonstrated that mesench […]<\/p>\n","protected":false},"author":1,"featured_media":2982,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[37],"tags":[],"class_list":["post-2979","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-heart-attack-heart-failure-lung-disease"],"acf":[],"yoast_head":"\nAutologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial. - Cytopeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial. - Cytopeutics\" \/>\n<meta property=\"og:description\" content=\"Background We have previously demonstrated that mesench […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0\" \/>\n<meta property=\"og:site_name\" content=\"Cytopeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T06:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T13:04:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2026\/01\/Paper3-Heart-disease-2016.png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1654\" \/>\n\t<meta property=\"og:image:height\" content=\"2339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#\\\/schema\\\/person\\\/72f689cc496b83192f8c287d93a8915f\"},\"headline\":\"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\\\/lll randomized controlled trial.\",\"datePublished\":\"2026-02-02T06:30:00+00:00\",\"dateModified\":\"2026-02-02T13:04:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0\"},\"wordCount\":355,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cytopeutics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Paper3-Heart-disease-2016.png.webp\",\"articleSection\":[\"Heart Attack, Heart Failure & Lung Disease\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0\",\"url\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0\",\"name\":\"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\\\/lll randomized controlled trial. - Cytopeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cytopeutics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Paper3-Heart-disease-2016.png.webp\",\"datePublished\":\"2026-02-02T06:30:00+00:00\",\"dateModified\":\"2026-02-02T13:04:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0#primaryimage\",\"url\":\"https:\\\/\\\/www.cytopeutics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Paper3-Heart-disease-2016.png.webp\",\"contentUrl\":\"https:\\\/\\\/www.cytopeutics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Paper3-Heart-disease-2016.png.webp\",\"width\":1654,\"height\":2339,\"caption\":\"Paper3- Heart disease 2016\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/abstracts-publication\\\/heart-attack-heart-failure-lung-disease\\\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\\\/\u00a0#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cytopeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\\\/lll randomized controlled trial.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/www.cytopeutics.com\\\/\",\"name\":\"Cytopeutics\",\"description\":\"Pioneering Stem Cell Research & Development\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cytopeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#organization\",\"name\":\"Cytopeutics\",\"url\":\"https:\\\/\\\/www.cytopeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cytopeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/New-Logo.png.webp\",\"contentUrl\":\"https:\\\/\\\/www.cytopeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/New-Logo.png.webp\",\"width\":600,\"height\":156,\"caption\":\"Cytopeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cytopeutics.com\\\/#\\\/schema\\\/person\\\/72f689cc496b83192f8c287d93a8915f\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/12bc1f46f5b9ae3ebe06ecbc387e5fcdf00b211f24e176b753f22f57a02a307a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/12bc1f46f5b9ae3ebe06ecbc387e5fcdf00b211f24e176b753f22f57a02a307a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/12bc1f46f5b9ae3ebe06ecbc387e5fcdf00b211f24e176b753f22f57a02a307a?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/staging.cytopeutics.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial. - Cytopeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0","og_locale":"zh_CN","og_type":"article","og_title":"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial. - Cytopeutics","og_description":"Background We have previously demonstrated that mesench […]","og_url":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0","og_site_name":"Cytopeutics","article_published_time":"2026-02-02T06:30:00+00:00","article_modified_time":"2026-02-02T13:04:17+00:00","og_image":[{"width":1654,"height":2339,"url":"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2026\/01\/Paper3-Heart-disease-2016.png.webp","type":"image\/webp"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"admin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"2 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0#article","isPartOf":{"@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0"},"author":{"name":"admin","@id":"https:\/\/www.cytopeutics.com\/#\/schema\/person\/72f689cc496b83192f8c287d93a8915f"},"headline":"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial.","datePublished":"2026-02-02T06:30:00+00:00","dateModified":"2026-02-02T13:04:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0"},"wordCount":355,"publisher":{"@id":"https:\/\/www.cytopeutics.com\/#organization"},"image":{"@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0#primaryimage"},"thumbnailUrl":"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2026\/01\/Paper3-Heart-disease-2016.png.webp","articleSection":["Heart Attack, Heart Failure & Lung Disease"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0","url":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0","name":"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial. - Cytopeutics","isPartOf":{"@id":"https:\/\/www.cytopeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0#primaryimage"},"image":{"@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0#primaryimage"},"thumbnailUrl":"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2026\/01\/Paper3-Heart-disease-2016.png.webp","datePublished":"2026-02-02T06:30:00+00:00","dateModified":"2026-02-02T13:04:17+00:00","breadcrumb":{"@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0#primaryimage","url":"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2026\/01\/Paper3-Heart-disease-2016.png.webp","contentUrl":"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2026\/01\/Paper3-Heart-disease-2016.png.webp","width":1654,"height":2339,"caption":"Paper3- Heart disease 2016"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytopeutics.com\/abstracts-publication\/heart-attack-heart-failure-lung-disease\/autologous-msc-infusion-improves-ejection-fraction-and-wall-thickness-in-severe-ischemic-cardiomyopathy-results-from-a-clinical-multicenter-phase-ll-lll-randomized-controlled-trial\/\u00a0#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cytopeutics.com\/"},{"@type":"ListItem","position":2,"name":"Autologous MSC infusion improves ejection fraction and wall thickness in severe ischemic cardiomyopathy: Results from a clinical multicenter phase ll\/lll randomized controlled trial."}]},{"@type":"WebSite","@id":"https:\/\/www.cytopeutics.com\/#website","url":"https:\/\/www.cytopeutics.com\/","name":"Cytopeutics","description":"Pioneering Stem Cell Research & Development","publisher":{"@id":"https:\/\/www.cytopeutics.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cytopeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/www.cytopeutics.com\/#organization","name":"Cytopeutics","url":"https:\/\/www.cytopeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.cytopeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2025\/09\/New-Logo.png.webp","contentUrl":"https:\/\/www.cytopeutics.com\/wp-content\/uploads\/2025\/09\/New-Logo.png.webp","width":600,"height":156,"caption":"Cytopeutics"},"image":{"@id":"https:\/\/www.cytopeutics.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.cytopeutics.com\/#\/schema\/person\/72f689cc496b83192f8c287d93a8915f","name":"admin","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/secure.gravatar.com\/avatar\/12bc1f46f5b9ae3ebe06ecbc387e5fcdf00b211f24e176b753f22f57a02a307a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/12bc1f46f5b9ae3ebe06ecbc387e5fcdf00b211f24e176b753f22f57a02a307a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/12bc1f46f5b9ae3ebe06ecbc387e5fcdf00b211f24e176b753f22f57a02a307a?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/staging.cytopeutics.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/posts\/2979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=2979"}],"version-history":[{"count":17,"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/posts\/2979\/revisions"}],"predecessor-version":[{"id":3366,"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/posts\/2979\/revisions\/3366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/media\/2982"}],"wp:attachment":[{"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=2979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=2979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cytopeutics.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=2979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}